Could a daily pill prevent dialysis catheter failures?
NCT ID NCT07404345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a low-dose blood thinner (apixaban) to the standard heparin lock can help dialysis catheters stay functional longer. Fifty-four adults with end-stage kidney disease and a new catheter will be followed for up to 24 months. The goal is to see if this combination reduces the need for emergency treatments or catheter replacement.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Apixaban (a blood thinner) and heparin (a standard catheter lock solution)
What this could lead to
If it works, this could reduce the need for emergency procedures or catheter replacements in dialysis patients, making treatment smoother.
What could go wrong
This is a small, early-phase trial (54 people) at a single center. The blood thinner may increase bleeding risk, and results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS ACCESS FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde"
Guadalajara, Jalisco, 44200, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••